Rising Pharma Holdings, Inc. is recalling an additional 13,567 bottles of Chlorthalidone Tablets, USP, 25 mg after the medication again failed dissolution specifications during quality control testing — meaning the tablets may not dissolve properly and could deliver less effective blood pressure control. The recall was initiated September 3, 2026, by manufacturer Inventia Healthcare Limited of India, and classified Class II by the FDA on September 17, 2026. No adverse events have been reported. This is Inventia Healthcare’s second chlorthalidone recall this year — in June 2026, the same manufacturer recalled 11,460 bottles of the same medication for the same reason.
What’s Being Recalled?
The recall covers Chlorthalidone Tablets, USP, 25 mg, packaged in 100-tablet bottles, with an expiration date of April 2027. The specific lot number for this recall is available in the FDA’s enforcement report at fda.gov under recall number D-0852-2026. The tablets were distributed nationwide by Rising Pharma Holdings, Inc.
Why Was This Product Recalled?
The tablets failed dissolution specifications for the second time this year — meaning quality control testing found they do not dissolve at the rate and completeness required. When a tablet fails dissolution standards, the full prescribed dose may not be absorbed, making the medication less effective. For patients relying on chlorthalidone to manage high blood pressure, consistently under-effective doses could increase the risk of stroke, heart attack, and kidney damage over time. The fact that this is the same manufacturer’s second recall for the same defect in a single year raises significant quality control concerns. The combined total of both 2026 recalls now exceeds 25,000 bottles of the same medication.
What Should You Do?
Do not stop taking chlorthalidone without first consulting your prescribing doctor or pharmacist — abruptly discontinuing blood pressure medication can cause a dangerous rebound spike in blood pressure. Contact your pharmacy to check whether your specific bottle is from the recalled lot and to arrange a replacement from an unaffected lot. Check the FDA enforcement report at fda.gov (recall number D-0852-2026) for the specific lot number. Report any adverse events to the FDA’s MedWatch program at fda.gov/safety/medwatch or call 1-800-332-1088.
